Efficacy and Tolerability of Benzodiazepines for the Treatment of Behavioral and Psychological Symptoms of Dementia: A Systematic Review of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The objective of this review is to summarize the available data on the use of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia (BPSD) from randomized controlled trials (RCTs). A systematic search of 5 major databases, PubMed, MEDLINE, PsychINFO, EMBASE, and Cochrane Collaboration, yielded a total of 5 RCTs. One study compared diazepam to thioridazine, 1 trial compared oxazepam to haloperidol and diphenhydramine, 1 trial compared alprazolam to lorazepam, 1 trial compared lorazepam to haloperidol, and 1 trial compared intramuscular (IM) lorazepam to IM olanzapine and placebo. The data indicates that in 4 of the 5 studies, there was no significant difference in efficacy between the active drugs to treat the symptoms of BPSD. One study indicated that thioridazine may have better efficacy than diazepam for treating symptoms of BPSD. In 1 study, the active drugs had greater efficacy in treating BPSD when compared to placebo. There was no significant difference between the active drugs in terms of tolerability. However, in 2 of the 5 studies, about a third of the patients were noted to have dropped out of the studies. Available data, although limited, do not support the routine use of benzodiazepines for the treatment of BPSD. But these drugs may be used in certain circumstances where other psychotropic medications are unsafe for use in individuals with BPSD or when there are significant medication allergies or tolerability issues with certain classes of psychotropic medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
Meta-analysis of the Impact of 9 Medication Classes on Falls in Elderly Persons
Woolcott, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.357 · Cited by 1,326 · cited 1×
“They are associated with increased risk of falls and fracture.(38,39) Benzodiazepines are also implicated in the development of cognitive dysfunction and increasing the risk of dementia.”
BackgroundLyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.8.1049 · Cited by 744
Livingston, G., Johnston, K., Katona, C., Paton, J., Lyketsos, C. G., & Old Age Task Force of the World Federation of Biological Psychiatry (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.1996 · Cited by 591
Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552 · cited 1×
“Benzodiazepines are also implicated in the development of cognitive dysfunction and increasing the risk of dementia.(40,41) Benzodiazepines may cause severe adverse effects when coadministered with certain medications like the opioids.”
BackgroundBenzodiazepine use and risk of dementia: prospective population based study
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.-F., Peres, K., Kurth, T., & Pariente, A. (2012) · BMJ · doi:10.1136/bmj.e6231 · Cited by 436
Management of agitation and aggression associated with Alzheimer disease
Ballard, C. G., Gauthier, S., Cummings, J. L., Brodaty, H., Grossberg, G. T., Robert, P., & Lyketsos, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.39 · Cited by 404 · cited 2×
“for those behaviors that are refractory to management with nonpharmacological approaches.(21) Along with antipsychotic medications, benzodiazepines are often prescribed in nursing homes to treat behavioral symptoms of dementia despite lack of an appropriate indication.”
BackgroundMethodAntidepressants for agitation and psychosis in dementia
Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N., & Rochon, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008191.pub2 · Cited by 304 · cited 1×
“The use of antidepressants for the treatment of BPSD indicates limited benefit although they have a fairly benign adverse effect profile.(47,48) The role of cholinesterase inhibitors and memantine for the treatment of BPSD still remains unclear.”
Incontinence and Troublesome Behaviors Predict Institutionalization in Dementia
O'Donnell, B. F., Drachman, D. A., Barnes, H. J., Peterson, K. E., Swearer, J. M., & Lew, R. A. (1992) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/002383099200500108 · Cited by 297
Lonergan, E., Luxenberg, J., & Areosa Sastre, A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006379.pub3 · Cited by 223 · cited 1×
“However, we did find a meta-analysis for the use of benzodiazepines for delirium, which indicated that there are no adequately controlled trials that was found to support the use of benzodiazepines in the treatment of nonalcohol withdrawalrelated delirium among hospitalized individuals and that at this time benzodiaze…”
Fourrier, A., Letenneur, L., Dartigues, J., Moore, N., & Bégaud, B. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100326 · Cited by 158
The Epidemiology of Long-Term Benzodiazepine Use
Neutel, C. I. (2005) · International Review of Psychiatry · doi:10.1080/09540260500071863 · Cited by 148
Konovalov, S., Muralee, S., & Tampi, R. R. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207006540 · Cited by 126
Self-citationHolbrook, A., Crowther, R., Lotter, A., & Endeshaw, Y. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49161.x · Cited by 61 · cited 1×
“There was no dose–response relationship for the beneficial effect seen with the use of benzodiazepines.(35) The data from the current review could be positioned between the results of these 2 meta-analyses.”
Background
Cited by
Brandt, J., & Leong, C. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0207-7 · Cited by 356
Management of Behavioral and Psychological Symptoms of Dementia
Bessey, L. J., & Walaszek, A. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1049-5 · Cited by 288
Lukačišinová, A., Fialová, D., Peel, N. M., Hubbard, R. E., Brkic, J., Onder, G., Topinková, E., Gindin, J., Shochat, T., Gray, L., et al. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02213-x · Cited by 35
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
Conn, D. K., Hogan, D. B., Amdam, L., Cassidy, K.-L., Cordell, P., Frank, C., Gardner, D., Goldhar, M., Ho, J. M.-W., Kitamura, C., et al. (2020) · Canadian Geriatrics Journal · doi:10.5770/cgj.23.419 · Cited by 32
Metadata
- Authors
- Tampi, R. R., & Tampi, D. J.
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2014-03-06
- Volume
- 29
- Issue
- 7
- Pages
- 565-574
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- OpenAlex
- W2025140794
- Cited by
- 90
- References
- 18
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.